VBI Vaccines (VBIV) 1901 Response Could Improve from GSK's AS01B Adjuvant - BMO
Tweet Send to a Friend
BMO Capital analyst Do Kim reiterated an Outperform rating and $5.00 price target on VBI Vaccines (NASDAQ: VBIV) on the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
